Abstract:This article has been retracted at the request of the Editor-in-Chief due to concerns regarding the legitimacy of images and data presented in the paper. Though a corrigendum (Can. Lett. Vol. 469, 2020, pages 524-535) was previously published to address some of these concerns, this corrigendum has also been found to contain errors and therefore cannot stand. Specific concerns are listed below. The Editor and Publisher received a letter from the University of Portsmouth alerting us to an investigation into alleged research misconduct. The University concluded their investigation with external experts and determined that misconduct did take place in relation to the research involved in this paper. Upon our separate investigation, it has been determined that the paper headline relies on showing that there was considerable reduction of IGF1R, IL6R and EGFR post treatment in all cell lines. During review, it was determined that this cannot be concluded from the presented data. For example, in SEBTA-003 the EGFR levels go up and there is no difference in IGFR1. It is apparent from Fig 4d that in the SEBTA-003 cell line the EGFR level does not go down, which is stated in the Results section on page 32, it is rather going up. The data for IGFR1 are inconclusive and there are concerns regarding the blot. The general implications would be that the effects of the drug IP1867B does not seem to be the same for all tested cell lines, and this should have been discussed in detail by the authors. Additionally, in subsequent experiments (Fig. 4g and h) the SEBTA-003 cell line (no reduction of EGFR, rather increased expression) and the other 3 cell lines (reduction of EGFR) show similar responses. This is particularly evident in Fig. 4g: Two cell lines are compared, SEBTA-003 (increased EGFR expression) and UP-029 (decreased EGFR expression), both behave similarly after exposure to drugs. The corrigendum (https://doi.org/10.1016/j.canlet.2019.10.002) issue is with respect to the Supplemental Figure 6i EGFR, particularly panel IP1867B. The Corrigendum states that the left part is a cut out of the very right part. If so, the bands for IP1867B should show the same staining pattern - but they do not. Also, in the Corrigendum, there are incorrect mentions between day 14 in the Figure and day 19 in the Figure legend. All authors were informed of the retraction in advance. Drs. Pritchard and Duckworth agreed to the retraction. The corresponding author, Dr Hill, did not agree to the retraction. No response had been received from Drs. Mihajluk, Simms, Reay, Madureira, Howarth, Murray, Nasser and Pilkinton at the time of the retraction being published.

RETRACTION: An MSN-PEG-IP drug delivery system and IL13R2 as targeted therapy for glioma (Retraction of Vol 9, Pg 8970, 2017)

Retraction: an MSN-PEG-IP Drug Delivery System and IL13Rα2 As Targeted Therapy for Glioma.

RETRACTION: Long Non Coding RNA SLC26A4-AS1 Exerts Antiangiogenic Effects in Human Glioma by Upregulating NPTX1 Via NFKB1 Transcriptional Factor

Retraction: Cell Membrane Based Biomimetic Nanocomposites for Targeted Therapy of Drug Resistant EGFR-mutated Lung Cancer

Retraction: Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer

Retracted: si-PDGFRβ-Loaded Exosomes Suppress the Progression of Glioma by Inhibiting the Oxidative Associated PI3K/Akt/EZH2 Signaling Pathway

RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas

RETRACTION: Radio-photothermal Therapy Mediated by a Single Compartment Nanoplatform Depletes Tumor Initiating Cells and Reduces Lung Metastasis in the Orthotopic 4T1 Breast Tumor Model (retraction of Vol 7, Pg 19438, 2015)

RETRACTION: CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10

[Retracted] AdipoR1‐mediated miR‐3908 inhibits glioblastoma tumorigenicity through downregulation of STAT2 associated with the AMPK/SIRT1 pathway

Retraction Note: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors

WITHDRAWN: Dual Targeting of Glioma U251 Cells and Neovasculature with a Nanoparticle Encoding Vasohibin and RGD Peptides Prevents Tumor Angiogenesis and Inhibits Tumor Growth

RETRACTION: Long Non-coding RNA Linc-ITGB1 Knockdown Inhibits Cell Migration and Invasion in GBC-SD/M and GBC-SD Gallbladder Cancer Cell Lines (Retraction of Vol 86, Pg 1064, 2015)

[Retracted] MicroRNA‐140 represses glioma growth and metastasis by directly targeting ADAM9

Retracted: Silencing of Long Noncoding RNA HLA Complex P5 (HCP5) Suppresses Glioma Progression through the HCP5-miR-205-Vascular Endothelial Growth Factor A Feedback Loop

RETRACTED ARTICLE: Mir-135 Promotes Proliferation and Stemness of Oesophageal Squamous Cell Carcinoma by Targeting RERG

RETRACTED ATICLE: Physcion 8-O-β-glucopyranoside Exerts Protective Roles in High Glucose-Induced Diabetic Retinopathy Via Regulating Lncrna NORAD/miR-125/STAT3 Signalling

RETRACTION: Suppression of microRNA-342-3p increases glutamate transporters and prevents dopaminergic neuron loss through activating the Wnt signaling pathway via p21-activated kinase 1 in mice with Parkinson's disease (Retraction of Vol 234, Pg 9033, 2019)

[Retracted] Serum miR‐338‐5p has potential for use as a tumor marker for retinoblastoma

RETRACTED: Mir-539 Enhances Chemosensitivity to Cisplatin in Non-Small Cell Lung Cancer by Targeting DCLK1

In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment [Retraction]